Is there a role for new drugs with alkylating properties in multiple myeloma?
Mené sur 23 puis 58 patients atteints d’un myélome multiple réfractaire ou récidivant, cet essai international de phase I/II évalue la dose maximale tolérée du melflufen et son efficacité, du point de vue du taux de réponse globale, en combinaison avec la dexaméthasone, après l’échec de deux ou plus lignes de traitements (incluant du lénalidomide et du bortézomib)
Multiple myeloma, a complex disease originating in plasma cells, was primarily treated with melphalan until the last years of the 20th century. Advances in knowledge of the biology of the disease have led to the introduction of new drugs, and its transition of new drugs from the relapse setting to first-line treatment has been fast and as a result, most patients with multiple myeloma will receive proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies targeting CD38 as part of the first line of therapy.
The Lancet Hematology , commentaire, 2019